Lung MAP employs a "master protocol" approach, which allows multiple treatments to be tested simultaneously within a single clinical trial structure. This is done by first performing comprehensive genomic profiling on patients' tumors to identify specific genetic alterations. Based on the results, patients are then assigned to different treatment arms that are most likely to be effective for their particular cancer subtype. This approach not only streamlines the clinical trial process but also enhances the likelihood of finding effective treatments more quickly.
